Earlier this week we reported that bi-coastal biotech Fate Therapeutics had named its new CEO, Paul Grayson. Today the company officially announced Grayson, as well as the appointment of John Mendlein as executive chairman. Mendlein was most recently CEO of Boston-based Adnexus Therapeutics, which was bought by Bristol-Myers Squibb last October for more than $505 million. Fate Therapeutics is backed chiefly by Polaris Venture Partners in Waltham, MA, and Arch Venture Partners in Seattle, WA.
Author: Gregory T. Huang
Greg is a veteran journalist who has covered a wide range of science, technology, and business. As former editor in chief, he overaw daily news, features, and events across Xconomy's national network. Before joining Xconomy, he was a features editor at New Scientist magazine, where he edited and wrote articles on physics, technology, and neuroscience. Previously he was senior writer at Technology Review, where he reported on emerging technologies, R&D, and advances in computing, robotics, and applied physics. His writing has also appeared in Wired, Nature, and The Atlantic Monthly’s website. He was named a New York Times professional fellow in 2003.
Greg is the co-author of Guanxi (Simon & Schuster, 2006), about Microsoft in China and the global competition for talent and technology. Before becoming a journalist, he did research at MIT’s Artificial Intelligence Lab. He has published 20 papers in scientific journals and conferences and spoken on innovation at Adobe, Amazon, eBay, Google, HP, Microsoft, Yahoo, and other organizations. He has a Master’s and Ph.D. in electrical engineering and computer science from MIT, and a B.S. in electrical engineering from the University of Illinois, Urbana-Champaign.
View all posts by Gregory T. Huang